Heat Biologics (HTBX) Says on Track to Report HS-410 and HS-110 Phase 1b, Phase 2 Data This Quarter

October 13, 2016 7:03 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Heat Biologics, Inc. (Nasdaq: HTBX) announced that it continues to remain on track to report topline data this quarter from its Phase 2 trials evaluating HS-410 and HS-110 for the treatment of non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), respectively, as well as its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, Opdivo®, for the treatment of NSCLC.

“We are pleased with the progress we are making and look forward to reporting top-line data in both our NMIBC and NSCLC trials later this quarter,” commented Jeff Wolf, Heat’s Founder and CEO. “We are encouraged by our early data in bladder cancer that suggests we are activating a robust antigen-specific immune response and our data in lung cancer that suggest HS-110 may improve response rates for patients with ‘cold tumors’ who typically have lower response rates to checkpoint inhibitor monotherapy.”

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Related Entities


Add Your Comment